United States Biotechnology & Medical Research

Aligos Therapeutics Inc (ALGS)

Track

Track

Aligos Therapeutics Inc has recorded no insider trading activity within the past ninety days. The most recent transaction occurred on October 25, 2023, involving a purchase by Carole Nuechterlein. Historical data indicates significant acquisition patterns by various entities and individuals dating back to 2020, though no recent market participation by company insiders is currently observed.
Ticker: ALGS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Nuechterlein Carole Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.17
Quantity 76,402 +2.1%
Value US$4,314,490
2.3
Novo Holdings A/S Large shareholder
Transaction date
Purchase
Price
462.52
Quantity 30,973 +30.4%
Value US$3,016,277
3.8
Woiwode Thomas Non-Executive Director
Transaction date
Purchase
Price
467.89
Quantity 83,694 -13.4%
Value US$4,563,346
3.7
Vivo Capital VIII, LLC Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 66,733 +18.4%
Value US$1,000,995
3.7
Vivo Capital VIII, LLC Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 483,267 +18.4%
Value US$7,249,005
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-10-27 2023-10-25 B Purchase
Nuechterlein Carole
Non-Executive Director Large shareholder
76,402 +2.1%
11.17
US$4,314,490 		76,402 +2.1% 11.17 US$4,314,490
2020-10-22 2020-10-20 B Purchase
2.3
Novo Holdings A/S
Large shareholder
30,973 +30.4%
462.52
US$3,016,277 		30,973 +30.4% 462.52 US$3,016,277
2020-10-20 2020-10-20 B Purchase
3.8
Woiwode Thomas
Non-Executive Director
83,694 -13.4%
467.89
US$4,563,346 		83,694 -13.4% 467.89 US$4,563,346
2020-10-20 2020-10-20 B Purchase
3.5
Versant Venture Capital VI, L.P.
Large shareholder
200,000 +30.2%
15.00
US$3,000,000 		200,000 +30.2% 15.00 US$3,000,000
2020-10-20 2020-10-20 B Purchase
3.7
Vivo Capital VIII, LLC
Large shareholder
66,733 +18.4%
15.00
US$1,000,995 		66,733 +18.4% 15.00 US$1,000,995
2020-10-20 2020-10-20 B Purchase
3.7
Vivo Capital VIII, LLC
Large shareholder
483,267 +18.4%
15.00
US$7,249,005 		483,267 +18.4% 15.00 US$7,249,005
Explore more

More insider trading research around Aligos Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America